Received May 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9SB34 | — |
Muscle weakness both hips, both knees, both shoulders; joint pain in both hips, both knees, both shoulders; This non-serious case was reported by a consumer and described the occurrence of muscle weakness in a 69-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 9SB34) for prophylaxis. On 22-APR-2025, the patient received Arexvy .5 ml. On 25-APR-2025, 3 days after receiving Arexvy, the patient experienced muscle weakness (Verbatim: Muscle weakness both hips, both knees, both shoulders) and joint pain (Verbatim: joint pain in both hips, both knees, both shoulders). The outcome of the muscle weakness and joint pain were not resolved. It was unknown if the reporter considered the muscle weakness and joint pain to be related to Arexvy. It was unknown if the company considered the muscle weakness and joint pain to be related to Arexvy. Additional Information: GSK Receipt Date: 11-MAY-2025 Patient experienced muscle weakness and joint pain in both hips, both knees and both Shoulders after Arexvy administration.